<unk>  (EHHB), sold under a number of brand names including Benzo-Ginoestril A.P., BenzoGynoestryl Retard, Ginestryl-15-Depot, Menodin, and Tardoginestryl, is an estrogen medication which was previously used for indications such as menopausal hormone therapy and gynecological disorders. EHHB is given by injection into muscle at regular intervals, for instance once every few weeks. Side effects of EHHB include breast tenderness, breast enlargement, nausea, headache, and fluid retention. EHHB is a synthetic estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It is an estrogen ester and a prodrug of estradiol in the body. Because of this, it is considered to be a natural and bioidentical form of estrogen. EHHB was first described in 1956, and was introduced for medical use by 1957. It was used in France. The medication should not be confused with estradiol benzoate (EB), which has been marketed under similar brand names including Benzo-Ginestryl, Benzo-Ginoestril, and Benzo-Gynoestryl.
Estradiol hexahydrobenzoate
Estradiol diundecylate
Estradiol monopropionate
Testosterone hexahydrobenzoate
Estradiol dibutyrate
Estradiol palmitate
Estriol glucuronide
Polyestriol phosphate